MedTrace Logo

TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment

NCT00140309 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2007-03-19

No results posted yet for this study

Summary

This study is a placebo-controlled factorial study, randomized to study drug (moxifloxacin vs. ethambutol) and treatment frequency (daily vs. thrice weekly after an initial two weeks of daily therapy) during the first two months of standard treatment (with isoniazid, rifampin, and pyrazinamide) for sputum smear-positive pulmonary tuberculosis.

Conditions

  • Tuberculosis, Pulmonary

Interventions

DRUG

moxifloxacin (with isoniazid, rifampin, pyrazinamide)

Sponsors & Collaborators

Principal Investigators

  • William Burman, MD · Denver Public Health Department

  • Richard E Chaisson, MD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-07-31
Completion
2005-12-31

Countries

  • United States
  • Canada
  • South Africa
  • Uganda

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00140309 on ClinicalTrials.gov